BOOTS DERMA CARE EMOLLIENT CREAM
Active substance(s): ALMOND OIL / ANHYDROUS LANOLIN
NAME OF THE MEDICINAL PRODUCT
Boots Skin Therapy Emollient Cream or Boots Derma Care Emollient Cream
QUALITATIVE AND QUANTITATIVE COMPOSITION
Almond Oil BP '88
Anhydrous Lanolin EP
For the relief of dry skin conditions such as chapping caused by weather or
water, nappy soreness, dry eczema and sunburn.
For topical application.
Posology and Method of Administration
Adults, children and the elderly
Apply to the affected area two or three times a day.
Hypersensitivity to any of the ingredients.
Special Warnings and Special Precautions for Use
Interactions with other Medicinal Products and other forms of
Pregnancy and Lactation
No special precautions are required in pregnancy and breast feeding mothers.
Effects on Ability to Drive and Use Machines
This product has no effect on the ability to drive or operate machinery.
Adverse reactions are unlikely, but may cause an allergic skin reaction, in
which case use of the product should be discontinued.
This product has low toxicity. If accidental ingestion occurs, conservative
treatment only is required.
Lanolin and almond oil help to moisturise the skin and prevent soreness.
Preclinical Safety Data
There are no preclinical data of relevance to the prescriber which are
additional to that already included.
List of excipients
White soft paraffin
Citric acid anhydrous
Special Precautions for Storage
Nature and contents of container
Lacquered collapsible aluminium tube with a polypropylene or polythene
Pack sizes: 50g, 60g
A polypropylene securitainer with a polythene pilfer-proof screw cap.
Pack size: 300g, 325g, 350g
Polypropylene pump dispenser with polyethylene plunger
Pack size: 100ml
Pump pack consisting of a polypropylene jar and a polyethylene,
polypropylene pump dispenser.
Pack sizes: 300g, 500g
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
The Boots Company PLC
1 Thane Road West
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION/RENEWAL OF
19 May 1988
15 September 1993
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency